

1 **To what extent do we need to rely on non-pharmaceutical interventions while**

2 **COVID-19 vaccines roll out in 2021?**

3

4 Juan Yang<sup>1,2\*</sup>, Valentina Marziano<sup>3\*</sup>, Xiaowei Deng<sup>1</sup>, Giorgio Guzzetta<sup>3</sup>, Juanjuan

5 Zhang<sup>1,2</sup>, Filippo Trentini<sup>3</sup>, Jun Cai<sup>1</sup>, Piero Poletti<sup>3</sup>, Wen Zheng<sup>1</sup>, Wei Wang<sup>1</sup>, Qianhui

6 Wu<sup>1</sup>, Zeyao Zhao<sup>1</sup>, Kaige Dong<sup>1</sup>, Guangjie Zhong<sup>1</sup>, Cécile Viboud<sup>4</sup>, Stefano Merler<sup>3†</sup>,

7 Marco Ajelli<sup>5,6†</sup>, Hongjie Yu<sup>1,2,7†</sup>

8

9 1. Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health,

10 Fudan University, Shanghai, China

11 2. Fudan University, Key Laboratory of Public Health Safety, Ministry of Education,

12 Shanghai, China

13 3. Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy

14 4. Division of International Epidemiology and Population Studies, Fogarty

15 International Center, National Institutes of Health, Bethesda, MD, USA

16 5. Department of Epidemiology and Biostatistics, Indiana University School of

17 Public Health, Bloomington, IN, USA

18 6. Laboratory for the Modeling of Biological and Socio-technical Systems,

19 Northeastern University, Boston, MA, USA

20 7. Department of infectious diseases, Huashan Hospital, Fudan University, Shanghai,

21 China

22

23 \*These authors contributed equally to this work.

24 †These authors are joint senior authors contributed equally to this work.

25

26 Corresponding authors: Marco Ajelli, Department of Epidemiology and Biostatistics,

27 Indiana University School of Public Health, 47405 Bloomington, IN, USA; E-mail:

28 marco.ajelli@gmail.com, and Hongjie Yu, , Shanghai Institute of Infectious Disease

29 and Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China

30 E-mail: yhj@fudan.edu.cn

31

32 **Word count (main text): 4,928**

33 **Word count (abstract): 148**

34 **Abstract**

35 COVID-19 vaccination is being conducted in over 190 countries/regions to control  
36 SARS-CoV-2 transmission and return to a pre-pandemic lifestyle. However,  
37 understanding when non-pharmaceutical interventions (NPIs) can be lifted as  
38 immunity builds up remain a key question for policy makers. To address it, we built a  
39 data-driven model of SARS-CoV-2 transmission for China. We estimated that to  
40 prevent the escalation of local outbreaks to widespread epidemics, stringent NPIs  
41 need to remain in place at least one year after the start of vaccination. Should NPIs  
42 alone be capable to keep the reproduction number ( $R_t$ ) around 1.3, the synergetic  
43 effect of NPIs and vaccination could reduce up to 99% of COVID-19 burden and  
44 bring  $R_t$  below the epidemic threshold in about 9 months. Maintaining strict NPIs  
45 throughout 2021 is of paramount importance to reduce COVID-19 burden while  
46 vaccines are distributed to the population, especially in large populations with little  
47 natural immunity.

48 The novel coronavirus disease 2019 (COVID-19) pandemic is far from over with  
49 cases still surging in many countries across the globe, particularly with India suffering  
50 from a catastrophic second wave <sup>1</sup>. In 2020, epidemic suppression and/or mitigation  
51 have relied on non-pharmaceutical interventions (NPIs), including social distancing,  
52 school closure, masking, and case isolation. Although effective and widely adopted to  
53 limit SARS-CoV-2 transmission and reduce COVID-19 burden, these interventions  
54 entail enormous economic costs and negatively affect quality of life <sup>2</sup>. Additionally, in  
55 many countries, relaxation of NPIs has led to a resurgence of the epidemic as herd  
56 immunity has not been reached thus far <sup>3</sup>.

57

58 Effective vaccines against COVID-19 remain the only foreseeable means of both  
59 suppressing the infection and returning to pre-pandemic social and economic activity  
60 patterns. Globally, several vaccines have been licensed, and vaccination programs  
61 have been initiated in more than 190 countries/regions, including China <sup>4</sup>. However,  
62 the projected global production and delivery capacities are likely to be inadequate to  
63 provide COVID-19 vaccines to all individuals who are still susceptible to  
64 SARS-CoV-2 infection <sup>3</sup>. The effectiveness of COVID-19 vaccination campaigns will  
65 depend on several factors, including pre-existing immunity, vaccine supply,  
66 willingness to receive the vaccine, and strategies for vaccine allocation and  
67 deployment <sup>5</sup>.

68

69 To avoid widespread transmission of SARS-CoV-2, since the end of the first

70 COVID-19 wave in the spring of 2020, China has implemented strict NPIs and has  
71 successfully controlled local outbreaks, preventing a second widespread wave of  
72 COVID-19. Since December 2020, China has given conditional approval for the use  
73 of four COVID-19 vaccines and emergency use approval for one. As of May 7, 2021,  
74 308 million doses (corresponding to 10.7% of the population) have been administered  
75 <sup>6</sup>. However, such a coverage is still extremely low and thus China remains highly  
76 vulnerable to importations of SARS-CoV-2 and onward transmission, as proved by  
77 several local outbreaks that occurred in the first four months of 2021, the largest of  
78 which occurring in Heilongjiang province led to 659 reported cases and spilled over  
79 to a neighboring province (419 cases were reported in Jilin) <sup>7</sup>. At present, estimating  
80 whether and when NPIs can be lifted, and the extent to which we need to rely on NPIs  
81 while vaccines roll out represents a top priority for policy making.

82

83 This question has not been well addressed in China, one of the few countries in the  
84 world where nearly the entire population is still susceptible to SARS-CoV-2 infection,  
85 and home to almost 1.4 billion individuals (roughly 18% of the world population). To  
86 fill this gap, we built on top of the wide body of work adopting mathematical models  
87 of the infection transmission process to evaluate vaccination programs <sup>8-12</sup>. In  
88 particular, we developed an age-structured stochastic model to simulate SARS-CoV-2  
89 transmission triggered by cases imported in mainland China, based on a  
90 susceptible-infectious-removed (SIR) scheme (Supplementary Fig.1). We consider a  
91 situation in which: i) no ongoing widespread SARS-CoV-2 transmission, ii) nearly no

92 immunity in the population, and iii) high risk of importing SARS-CoV-2 infected  
93 individuals, possibly leading to an upsurge of COVID-19 cases. Since COVID-19  
94 vaccines are expected to continue rolling out throughout 2021-2022, we consider also  
95 alternative scenarios where SARS-CoV-2 infections leading to an outbreak are  
96 imported when 10% (close to the coverage as of May 2021), 20%, and 30% of the  
97 Chinese population has already been vaccinated (according to the simulated  
98 vaccination program).

99

100 In the model, we account for heterogeneous mixing patterns by age<sup>13</sup> and progressive  
101 vaccine deployment among different population segments based on a priority scheme  
102 (essential workers, older adults and individuals with underlying conditions, etc.)<sup>14</sup>.

103 Further, we overlay a disease burden model on the transmission model to estimate the  
104 number of symptomatic cases, hospitalizations, ICU admissions, and deaths under  
105 different vaccination scenarios and based on empirical data<sup>15-20</sup>. The resulting  
106 integrated model is informed by data on COVID-19 natural history, age-mixing  
107 patterns specific to China quantified during the pre-pandemic period, and the size of  
108 the different vaccination targets in the Chinese population (e.g., individuals with  
109 pre-existing conditions). A qualitative model description is reported in the Methods  
110 section, a summary of model parameters and data sources is reported in

111 Supplementary Table 1, all other details are reported in Supplementary File 1-5.

112 The combined effect of NPIs and vaccination programs are evaluated in terms of their  
113 ability in reducing the disease burden caused by outbreaks arising from possible

114 importation of cases.

115

116 We considered a baseline vaccination scenario where: 1) vaccination starts 15 days  
117 after an outbreak triggered by 40 breakthrough imported SARS-CoV-2 infections; 2)  
118 vaccine efficacy (VE) against SARS-CoV-2 infections for a two-dose schedule (with a  
119 21-day interval) is set at 80% <sup>21</sup>; 3) vaccination coverage is capped at 70% across all  
120 ages <sup>14</sup>; 4) 6 million doses are administered daily (4 per 1,000 individuals, informed  
121 by the ongoing COVID-19 vaccination program <sup>6</sup>, and estimates of vaccine supply till  
122 2021 in China <sup>22-26</sup>); 5) the first priority target consists of older adults and individuals  
123 with underlying conditions (descriptions in details shown in Supplementary Table 2);  
124 6) there is no prior population immunity from natural infection, which aligns with the  
125 situation in most of China where there has been little circulation of SARS-CoV-2 as  
126 of May 2021 <sup>3</sup>; 7) we assume an initial reproductive number  $R_t = 2.5$  at the start of the  
127 outbreak <sup>27-32</sup>, in the absence of NPIs and vaccination; 8) Children under 15 years of  
128 age were considered to have a lower susceptibility to SARS-CoV-2 infection as  
129 compared to adults (i.e., individuals aged 15 to 64 years), while individuals aged 65+  
130 years had the highest susceptibility to infection (Supplementary Table 1) <sup>33,34</sup>; and 9)  
131 we let the model run for two years. To evaluate the impact of the baseline assumptions  
132 on our results, we conduct comprehensive sensitivity analyses (SA).

133

## 134 **Results**

### 135 **Main analysis**

136 In the absence of NPIs, the vaccination program is too slow to lower and delay the  
137 epidemic (Fig. 1a) and does not effectively reduce COVID-19 burden.  $R_t$  falls below  
138 the epidemic threshold ( $<1$ ) 69 days after the epidemic start (Fig. 1b), but this is  
139 primarily attributable to immunity gained through natural infection rather than  
140 vaccination. Indeed, in this time frame, 52.2% of population gets infected, while only  
141 6.7% of population has been vaccinated (Fig. 1c). The cumulative number of  
142 symptomatic cases and deaths over a 2-year period only decrease by 3.3% (95% CI,  
143 3.1%-4.7%) and 6.7% (95% CI, 4.5%-8.9%), respectively, as compared to a reference  
144 scenario where there is no vaccination and no NPIs, which would lead to 306.73  
145 million (95% CI, 282.68-320.60) symptomatic cases, 99.25 million (95% CI,  
146 92.55-104.51) hospitalizations, 7.19 million (95% CI, 6.00-7.83) ICU admissions, and  
147 9.38 million (95% CI, 7.70-10.26) deaths (Fig. 2).

148

149 Provided that NPIs are in place and can keep  $R_t$  at 1.3 in the absence of vaccination  
150 (*moderate NPIs scenario*), the vaccination program could reduce COVID-19 burden  
151 by about 99% compared to the *reference no-vaccination scenario*, with 5.46 million  
152 (95% CI, 2.47-13.36) symptomatic cases, 1.77 million (95% CI, 0.83-4.40)  
153 hospitalizations, 73,500 (95% CI, 7,300-152,100) ICU admissions, and 76,700  
154 (95% CI, 8,200-165,700) deaths (Fig. 2). In this context, vaccination decreases  
155 COVID-19 burden by about 40% (Fig. 2) compared to a situation with moderate NPI  
156 alone, and  $R_t$  falls below the epidemic threshold about 9 months after the epidemic  
157 start (Fig. 1). At the time that  $R_t$  falls below 1, we estimate that 50.8% of the total



158 population would have been vaccinated, while 0.8% would have been naturally  
159 infected (Fig. 1g-i). This highlights that a relevant proportion of the population would  
160 be still susceptible to SARS-CoV-2 at that time. Although in the long-term  
161 vaccination can ultimately lead to the suppression of transmission, it is necessary to  
162 maintain NPIs for one year after the onset of vaccination. Indeed, if NPIs are relaxed  
163 from moderate ( $R_t=1.3$ ) to mild ( $R_t=1.5$ ) 9 months after vaccination start, the  
164 cumulative death toll could increase from 76,700 to 173,000. In contrast, a small  
165 increase in cumulative deaths from 76,700 to 81,700 is expected if this relaxation  
166 occurs one year after vaccination start, while earlier or more drastic relaxations of  
167 NPIs lead to substantial increases in deaths (Extended Data Fig.1-3).

168

169 A combination of more stringent NPIs (i.e., capable of keeping  $R_t=1.1$ ) and  
170 vaccination (*vax + high NPIs* scenario) could suppress the epidemic, with <2,300  
171 symptomatic cases, and <50 deaths on average. Although the majority of the  
172 reduction of COVID-19 burden is ascribable to NPIs in this case (over 85%), the  
173 deaths averted due to vaccination are about 1.2 million (Fig. 1j-l, and Fig. 2).

174

175 If we consider a set of mild NPIs (*vax + mild NPIs* scenario), even a relatively low  
176 initial reproduction number under NPIs of  $R_t=1.5$  could still lead to a disastrous  
177 epidemic, with nearly two million deaths. Despite the high death toll of the resulting  
178 epidemic, NPIs and vaccination would jointly reduce around 80% of the disease  
179 burden compared to a scenario with no NPIs and no vaccination (namely, 239 million

180 symptomatic cases and 8.2 million deaths averted) (Fig. 1d-f, and Fig. 2).

181

## 182 **Vaccine distribution capacity**

183 Should the daily vaccination rollout be limited to 1.3 million doses (1 per 1,000  
184 individuals – a slower rate than during the 2009 H1N1 pandemic), vaccination would  
185 not effectively reduce COVID-19 related deaths unless there was adoption of  
186 stringent NPIs. In a scenario where vaccination capacity reaches 10 million doses  
187 administered per day (7 per 1,000 individuals), vaccination would reduce COVID-19  
188 related deaths to <5,000 for moderate NPIs and <30 for high NPIs. Should the daily  
189 vaccination capacity be increased to 15 million doses (10 per 1,000 individuals),  
190 vaccination could effectively reduce deaths to <100,000 (similar to the annual  
191 influenza-related death toll in China<sup>35</sup>) even in the presence of mild NPIs. However,  
192 even if the daily vaccination capacity could be increased to 30 million doses (20 per  
193 1,000 individuals), in the absence of NPIs, we estimate that over 7.7 million deaths  
194 would still occur (Fig. 3). Similar patterns are estimated for the number of  
195 symptomatic cases, hospitalizations and ICU admissions (Extended Data Fig.4-6).

196

197 Increasing daily vaccination capacity could largely shorten the time needed to control  
198 SARS-CoV-2 transmission. For instance, when considering a daily capacity of 10  
199 million and 15 million doses and moderate NPIs,  $R_t$  would drop below 1 about 8 and  
200 6 months respectively after epidemic onset (to be compared to the 9.3 months  
201 estimated with the baseline capacity of 6 million doses). At that time, over 60% of the

202 population would be vaccinated and  $\leq 0.1\%$  would be naturally infected. An upscale in  
203 the daily capacity to 10 or 15 million doses would allow a relaxation of NPIs from  
204 moderate to mild already 6 to 9 months after vaccination start, i.e., 3 to 6 months  
205 earlier with respect to the baseline. On the other hand, more drastic relaxations of  
206 NPIs (e.g., from moderate to no NPIs) would still lead to substantial increases in  
207 symptomatic cases and deaths (Extended Data Fig.7-10).

208

### 209 **Vaccination prioritization**

210 We consider alternative vaccination scenarios that prioritize essential workers (staff in  
211 the healthcare, law enforcement, security, community services, and individuals  
212 employed in cold chain, etc.) to maintain essential services and then explore different  
213 prioritization strategies for the rest of the population. Our results suggest that the  
214 relative timing of the epidemic and of the vaccination rollout play a key role in  
215 determining the most effective strategy. In particular if we consider vaccination to  
216 start two weeks after 40 cases are detected, there is no clear prioritization strategy that  
217 minimize deaths, as the outcome of the vaccination campaign heavily depends on the  
218 timing at which the epidemic unfolds (Fig. 4 and Extended Data Fig. 11-12). Instead,  
219 if the epidemic is already underway when the vaccination campaign starts ( $>5,000$   
220 cases), prioritizing working-age groups minimizes the number of deaths when  $R_t \leq 1.3$ .  
221 In contrast, prioritizing older adults and individuals with underlying conditions is  
222 more effective when  $R_t \geq 1.5$  (direct benefits are higher, Fig. 4 and Extended Data Fig.  
223 11-12). Two results are independent of the adopted prioritization strategy: i) if  $R_t \geq 1.5$ ,

224 then an epidemic cannot be avoided; and ii) when  $R_t = 1.1$ , over 99% of deaths can be  
225 averted (Extended Data Fig. 11-12).

226

### 227 **Population immunity at the onset of an outbreak**

228 In December 2020, vaccination has started in China, while measures to detect  
229 imported cases and case surveillance are in place. The number of doses distributed per  
230 day has changed over time, following an increasing trend and with a daily average of  
231 about 6 million doses over the period April 20 – May 7, 2021 (Supplementary File 3).  
232 As of May 7, 2021, the vaccination coverage is 10.7%<sup>6</sup>. The effectiveness of the  
233 vaccination program and NPIs in preventing new COVID-19 outbreaks and limiting  
234 COVID-19 burden will thus depend on the level of vaccine-induced immunity in the  
235 population should an outbreak of locally transmitted cases start to unfold.

236

237 To simulate this situation, we initialize the model by considering different fractions of  
238 vaccinated population ( $SA1$ : 10%;  $SA2$ : 20%;  $SA3$ : 30%) at the time the infection is  
239 seeded. Given a certain level of NPIs in the absence of immunity, increasing  
240 proportions of vaccinated individuals will decrease the effective reproduction number  
241 (e.g.,  $R_t = 1.1$  in the absence of immunity, corresponds to  $R_t$  below the epidemic  
242 threshold if 10% or more of the population has been vaccinated).

243

244 Should 30% of the population already been vaccinated before the start of a new wave,  
245 continuing the vaccination program while adopting mild NPIs would reduce the death

246 toll by 98% (42,400 deaths as compared 1.8 million if no one was vaccinated).

247 However, in the absence of NPIs, even if 30% of population was already vaccinated  
248 before the start of a new wave, carrying on with the vaccination program alone would  
249 not be enough to prevent a widespread epidemic leading to 6 (95% CI: 4-7) million  
250 deaths (Extended Data Fig.13).

251

### 252 **Vaccination coverage**

253 No significant difference in willingness-to-vaccination between age groups has been  
254 reported in China<sup>36-38</sup>. Accordingly, we use a homogenous vaccine coverage of 70%  
255 among all age groups in the main analysis. Here we present the results of a set of  
256 sensitivity analyses assuming vaccination coverage of 50% (SA4) and 90% (SA5)  
257 among all age groups, and considering heterogeneous coverages by age: 1) 70% for  
258 adults  $\geq 20$  years and 50% for younger individuals (SA6); 2) 90% for adults  $\geq 20$  years  
259 and 70% for younger individuals (SA7); 3) 70% for adults  $\geq 20$  years and no  
260 vaccination for younger individuals (SA8).

261

262 By considering moderate NPIs ( $R_t=1.3$ ) and a vaccination coverage of 50% in all age  
263 groups, the number of symptomatic is estimated to decrease by 33% with an 8%  
264 decrease of the death toll with respect to the baseline vaccination scenario (70%  
265 coverage) (Extended Data Fig.14-15). In fact, the lower coverage in older age groups  
266 would lead to an earlier vaccination in younger age groups who are characterized by  
267 the highest contact rates<sup>13</sup>. Conversely, increasing the coverage to 90% would

268 decrease the death tolls but lead to an increase of symptomatic cases (Extended Data  
269 Fig.14-15). It is important to remark that these results consider that moderate NPIs  
270 remain in place over the entire duration of the epidemic, and they do not provide  
271 indications of the coverage needed to suppress any further resurgences of cases.

272

273 As compared to the baseline vaccination scenario (70% vaccination coverage in all  
274 age groups), if the vaccine is not distributed among individuals aged less than 20  
275 years, we estimate an increase of the death toll of 69% and of symptomatic infections  
276 of 55% (Extended Data Fig.14-15). The scenario assuming 90% vaccination coverage  
277 for adults  $\geq 20$  years and 70% for younger individuals lead to a lower reduction of  
278 COVID-19 burden as compared with the baseline vaccination scenario (Extended  
279 Data Fig. 14-15). The higher coverage in the adult population result in a delayed start  
280 of vaccination of the young population, which is characterized by higher contacts  
281 rates<sup>13</sup>. Nonetheless, it is important to remark that this result depends on the timing of  
282 the introduction of the initial seeds (see previous section).

283

#### 284 **Vaccine efficacy**

285 Three types of COVID-19 vaccines are currently in use in China, including  
286 inactivated, recombinant protein subunit, and adenovirus-vectored vaccines. VE for  
287 these vaccines ranges from 65% to 90%, with the exception of the one tested in Brazil  
288 where P1 variant is prevalent (VE=50%)<sup>39-43</sup>. With respect to an 80% VE adopted in  
289 the baseline scenario, by considering VE=60% (SA9) we estimate a 1.02-fold increase

290 of the death toll and 1.64-fold increase of symptomatic cases. Whereas a 37% and 29%  
291 decrease of deaths and symptomatic cases, respectively, is estimated for VE=90%  
292 (SA10). (Extended Data Fig.14-15)

293

#### 294 **SARS-CoV-2 variants**

295 Multiple SARS-CoV-2 variants have been documented globally, three of which are of  
296 particular concern: lineage B.1.1.7 identified in UK, B.1.351 in South Africa, and P.1  
297 in Brazil<sup>44</sup>. These variants are estimated to have higher transmissibility<sup>45,46</sup> and  
298 possibly an increased mortality<sup>47,48</sup>. To assess the effect of vaccination in this context,  
299 we consider higher values of  $R_t$  (i.e., 1.7, 1.9, and 2.1 – about 30%-60% increased  
300 transmissibility with respect to the main analysis<sup>45</sup>) to account for enhanced  
301 transmissibility, and use a mean death hazard ratio of 1.64 to account for higher  
302 mortality<sup>47</sup>. With the assumption of VE=80% against the new variant, COVID-19  
303 burden substantially increases, compared to the scenario based on the historical  
304 lineage. The number of symptomatic cases increase from 2 thousand to 173 million,  
305 and death increase from <50 to 7 million even when strict NPIs are implemented  
306 (Extended Data Fig. 16).

307

#### 308 **Alternative vaccination parameters and scenarios**

309 A further set of sensitivity analyses are conducted to evaluate the impact of baseline  
310 assumptions on our results for  $R_t=1.3$  (moderate NPIs). Provided that vaccination can  
311 only protect against illness (SA11) but not SARS-CoV-2 infections, COVID-19 related

312 deaths increase by 33 folds with respect to the baseline: from 76,700 to 2.66 million  
313 (Extended Data Fig.14). In this case, maintaining stringent NPIs measures in place for  
314 a prolonged time horizon would be necessary as such vaccine would not be effective  
315 to suppress transmission (as reported in previous studies <sup>49</sup>). Assuming a shorter  
316 duration of vaccine-induced protection of 6 months (*SAI2*) instead of a lifelong  
317 protection (i.e., longer than the 2-year time horizon considered, Extended Data Fig.14)  
318 has a similarly large effect on projections.

319

320 In our main analysis, we use the contact matrix estimated from a contact survey  
321 conducted in Shanghai before the COVID-19 pandemic <sup>13</sup>. Should a new COVID-19  
322 wave start to unfold in China, it is unclear to what extent pre-pandemic contact  
323 patterns could be representative of such a situation. Therefore, we have added a  
324 sensitivity analysis where we assume the mixing patterns estimated in Shanghai in  
325 March 2020 <sup>50</sup>, when schools were still closed as a response to the COVID-19  
326 pandemic (*SAI3*). For  $R_t=1.3$  and the baseline parameters for the vaccination, the  
327 estimated number of deaths would be 16,000 as compared to 76,700 estimated using  
328 the pre-pandemic mixing patterns (79% decrease, see Extended Data Fig.14). In fact,  
329 the relative contribution of the adult population (which is the main target of the  
330 vaccination campaign) to the overall transmission as compared to children is higher  
331 than when considering pre-pandemic mixing patterns (when schools were open and  
332 school-age individuals had the highest number of contacts).

333



334 Other factors such as excluding detected symptomatic cases from vaccination (*SA14*  
335 and *SA15*), the time interval between two doses (*SA16 and SA17*), and assuming an  
336 all-or-nothing vaccine (*SA18*), do not substantially affect estimates of deaths and  
337 symptomatic infections (Extended Data Fig.14-15). A similar trend is observed for  
338 hospitalized cases and ICU admissions.

339

## 340 **Discussion**

341 Using a stochastic dynamic model of SARS-CoV-2 transmission and COVID-19  
342 burden tailored to the epidemiological situation in China, we find that in the absence  
343 of NPIs, and independently of the vaccine prioritization strategy and capacity of the  
344 vaccination campaign, timely rollout of an effective vaccine ( $VE = 80\%$ ) would not be  
345 enough to prevent a local outbreak to escalate to a major widespread epidemic.  
346 Provided that NPIs are in place and capable to bring  $R_t$  to 1.3, a daily vaccine rollout  
347 of 4 doses per 1,000 individuals could reduce around 99% of COVID-19 burden, and  
348 bring  $R_t$  below the epidemic threshold about 9 months after the start of the  
349 vaccination campaign. A relaxation of NPIs that bring the value of  $R_t$  to 1.5 could not  
350 prevent sustained epidemic growth which would cause 1.8 million deaths. A net  
351 reproduction number of 1.5 could only be sustained when accompanied by an  
352 improvement of the vaccine administration capacity up to 10 doses per 1,000  
353 individuals per day. Relaxation of NPIs in the first 6-9 months of vaccine rollout  
354 could lead to substantial increases of COVID-19 burden if daily vaccination capacity  
355 could not be enhanced to 10-15 million doses.

356

357 Bubar K, et al. evaluated COVID-19 vaccine prioritization strategies and found that  
358 prioritizing older adults is a robust strategy to minimize deaths across countries when  
359  $R_t=1.5$ , while prioritization shifted to 20-49 years group when  $R_t=1.15$ <sup>51</sup>. The broad  
360 scope of that multi-country analysis does not account for features of COVID-19  
361 epidemiology and vaccination program that are unique to China. In particular,  
362 differently from most countries where natural immunity is building up after  
363 widespread epidemics, China has been able to suppress SARS-CoV-2 transmission for  
364 most of 2020. As a result, prior immunity is very low, thus calling for specifically  
365 tailored analysis. Nonetheless, our findings confirm that if NPIs can maintain  
366 transmission rates at low levels during the vaccination campaign, strategies that target  
367 indirect benefits perform better, while if transmission rates remain high, strategies  
368 maximizing direct benefits may save more lives<sup>51</sup>.

369

370 As highlighted in vaccination studies in Italy<sup>52</sup>, in the race between the vaccination  
371 campaign to build population herd-immunity and the progress of the epidemic, the  
372 speed of vaccine deployment is critical. Considering the average vaccine distribution  
373 capacity of the current COVID-19 vaccination campaign in China<sup>6</sup>, we use 6 million  
374 doses administered per day in the baseline analysis. Several manufacturers state that a  
375 total of 3.9 billion doses of COVID-19 vaccine could be produced in 2021, equivalent  
376 to about 10 million doses per day<sup>22-26</sup>. China committed to provide COVID-19  
377 vaccines to >100 countries, and thus that could reduce the number of doses to be

378 distributed locally. Even if these candidate vaccines could be licensed and  
379 manufactured smoothly, it would take about one year to vaccinate 70% of the  
380 population.  
381  
382 Five months after initiating vaccination program, 10.7% of Chinese population has  
383 been vaccinated <sup>6</sup>. Limited vaccine production capacity, particularly at the initial stage,  
384 could slow the speed of vaccine rollout. Slower rates of vaccine production and  
385 administration may result in a longer period of SARS-CoV-2 transmission. It is thus  
386 crucial to keep monitoring local outbreaks and invest resources in outbreak  
387 management (as currently done in China) in order to keep  $R_t$  close to the epidemic  
388 threshold at least for the next 1-2 years. In the very unique context of China, a value  
389 of  $R_t$  of 1.3 would result in about 76,700 cumulative deaths, comparable to the annual  
390 influenza-related death toll in China<sup>35</sup>. The development of detailed logistical plans  
391 and tools to support an increased vaccination capacity as well as effective logistic  
392 (vaccine transport, storage, and continuous cold-chain monitoring) are key factors for  
393 a successful mass vaccination campaign.

394  
395 In the early phase of COVID-19 spread in Wuhan in 2019, before interventions were  
396 put in place,  $R_0$  was estimated to be in the range 2.0-3.5<sup>27-32</sup>. Given the knowledge of  
397 mechanisms of SARS-CoV-2 transmission, and the devastating consequences of an  
398 uncontrolled COVID-19 epidemic, the Chinese population would hold a precautious  
399 behavior (such as clean hands often, cough or sneeze in bent elbow, avoid close

400 contact with someone who is sick, etc.) even without the need to impose NPIs. As  
401 such, in our analysis simulating an epidemic triggered by imported cases, we decided  
402 to consider an initial R of 2.5, which is at the lower end of the estimated spectrum.  
403  
404 SARS-CoV-2 variants are circulating globally and quickly became dominant in  
405 countries like the UK and Italy (lineage B.1.1.7), and South Africa (lineage B.1.351).  
406 Recently, a variant B.1.617 identified in India has raised global concern. As of May 7,  
407 2021, Mainland China border control screenings have already identified imported  
408 cases with SARS-CoV-2 lineage B.1.1.7 and B.1.617. Our study shows that the spread  
409 of new more transmissible and/or more lethal variants could substantially decrease the  
410 net benefit of vaccination. Strict border quarantine and isolation as well as genomic  
411 surveillance will be key while vaccines roll out in China.  
412  
413 Our analysis on the vaccine efficacy shows that if we consider  $VE=60\%$ , both the  
414 number of symptomatic cases and deaths are estimated to double as compared to the  
415 baseline vaccination coverage of 80%. Given that the final composition of a  
416 nation-wide rollout will likely include a combination of vaccines with varying  
417 efficacy, monitoring vaccine effectiveness on the ground will remain a priority.  
418  
419 Here we propose a general framework to evaluate the impact of COVID-19  
420 vaccination programs in the absence/presence of NPIs and to explore priority target  
421 populations to minimize multiple disease outcomes. The proposed modeling

422 framework is adaptable to other country-specific contexts. However, it requires the  
423 collection of country-specific data about the epidemiological situation (e.g., landscape  
424 immunity of the local population, prevalence of infections), vaccination parameters  
425 (e.g., vaccine supply and capacity of immunization services, efficacy of different  
426 vaccines, target age groups), socio-demographic characteristics of the population (e.g.,  
427 size of the priority population by age group, age-mixing patterns), and the priorities of  
428 the pandemic responses (e.g., limit the death toll, prevent infections).

429

430 Our study has a number of limitations. First, we integrated the impact of NPIs through  
431 a simple reduction in the value of  $R_t$  at the beginning of the outbreak, homogeneously  
432 across age groups. However, our analysis does not suggest which combination of  
433 NPIs should be adopted to lower  $R_t$  to a certain level, and how this would affect  
434 transmission rates in different age groups. Li, et al, estimated that individual NPIs,  
435 including school closure, workplace closure, and public events bans, were associated  
436 with reductions in  $R_t$  of 13–24% on day 28 after their introduction<sup>53</sup>. Further studies  
437 are needed to pinpoint the specific NPIs to be adopted in parallel with the vaccination  
438 campaign and their impact on the quality of life of the population.

439

440 Second, in China, vaccines have not been licensed for children, so we assume a 50%  
441 lower or equivalent VE for them compared to other adults. Although we show that  
442 variations in these rates do not substantially affect the overall effect of the vaccination  
443 campaign, further data on age-specific vaccine efficacy could help refine priority

444 groups. Our sensitivity analyses on vaccine coverage reveal the importance of  
445 extending the vaccination to the young population once the use of vaccines will be  
446 authorized for that age segment of the population.

447

448 Third, we assumed that immunity after natural infections lasts more than the time  
449 horizon considered (two years). If this is not the case, waning of immunity would  
450 inflate the rate of susceptible individuals and thus require booster vaccinations. This  
451 could become an issue with the emergence of immune-escape variants, as reported in  
452 South Africa<sup>54</sup>. Given limited information at this stage, we did not consider this  
453 scenario in our analyses, but this is an important area of future research.

454

455 Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals  
456 of different ages are exposed to different transmission risks. In the main analysis, we  
457 assumed the mixing patterns to correspond to those estimated before the COVID-19  
458 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also  
459 performed a sensitivity analysis based on the mixing patterns estimated in China in  
460 March 2020<sup>50</sup>, after the lockdown was lifted but schools were still closed. How the  
461 population would mix in case of a new wave of COVID-19 starts to unfold in China  
462 remains to be seen.

463

464 Moreover, our study is performed at a national scale and thus our estimates of the  
465 impact of vaccination should be interpreted cautiously at the local scale. In fact,

466 spatial heterogeneities within China in terms of risk of case importation,

467 socio-demographic characteristics of the population, mixing and mobility patterns,

468 vaccination coverage and capacity may affect our results.

469

470 Enhanced vaccination efforts in conjunction with NPIs have been successfully used

471 during the COVID-19 outbreak in Ruili city (Yunnan Province, China) in March-April,

472 2021. Our analysis, however, focuses on the assessment of whether and to what extent

473 we need to rely on NPIs to prevent a COVID-19 epidemic while vaccines are rolled

474 out. As such, our results cannot be used to guide a reactive spatially targeted strategy.

475 To properly capture the peculiarity of that context, specific modeling tools mirroring

476 the interventions adopted in China as a response to emerging outbreaks are needed.

477

478 Finally, it would be interesting to analyze adaptive vaccination prioritizations that

479 changes as the epidemiological situation evolves over time but that would require the

480 development of dynamic optimization algorithms that are beyond the scope of this

481 work<sup>55</sup>. Nonetheless, our study provides estimates of the effect of relaxing NPIs over

482 the course of the epidemic.

483

484 In conclusion, vaccination alone could substantially reduce COVID-19 burden, but in

485 the foreseeable future may not be enough to prevent local outbreaks to escalate to


486 major widespread epidemics due to limitation in the vaccine production and supply

487 (particularly at the initial stage of the vaccination), as well as the capacity of

488 vaccination system. This is especially relevant in contexts where most of the  
489 population is still susceptible to SARS-CoV-2 infection, as it is the case in most of  
490 China. Maintaining NPIs (such as social distancing, testing, case isolation and contact  
491 tracing, wearing masks, and limitation on large gatherings) throughout 2021 is  
492 necessary to prevent the resurgence of COVID-19 epidemics until a sufficiently high  
493 level of immunity is reached, which depends on the transmissibility of the variants  
494 circulating at that time.



495 **Figure legend**



496


497 **Figure 1. Time series of symptomatic cases, effective reproductive number  $R_t$ ,**

498 **and population infected and vaccinated.**

499 a) Number of symptomatic cases over time as estimated in the no-NPIs scenario

500 (initial  $R_t=2.5$ ) in the absence/presence of vaccination. b) Net reproduction number  $R_t$   
501 over time, as estimated using a Bayesian framework (Supplementary File 6) from the  
502 time series of symptomatic cases in the no-NPIs scenario in the presence of  
503 vaccination. The horizontal line indicates the epidemic threshold  $R_t=1$  and the vertical  
504 line indicates where  $R_t$  cross this threshold. Note that for the first few generations of  
505 cases,  $R_t$  shows an increasing pattern linked to the highly stochastic nature of  
506 epidemics in their initial phase when epidemics with initially larger  $R_t$  are more likely  
507 to survive<sup>56</sup>. c) Absolute numbers and proportion of the Chinese population infected  
508 and vaccinated over time in the no-NPIs scenario in the presence of vaccination. The  
509 population size of China in 2020 is 1,439,324,000<sup>57</sup>. d)-f): as a-c but for the mild  
510 NPIs scenario (initial  $R_t=1.5$ ). g)-i): as a-c but for the moderate NPIs scenario (initial  
511  $R_t=1.3$ ); j)-l): As a-c but for the high NPIs scenario (initial  $R_t=1.1$ ). Line denotes  
512 median, and shadow denotes quantiles 0.025 and 0.975.

513



514

515 **Figure 2. Burden of COVID-19 in the main analysis.**

516 a) Cumulative number of symptomatic cases as estimated under the different

517 scenarios in the absence/presence of vaccination over the simulated 2-year period. No

518 vaccination + no NPIs with  $R_t=2.5$  at the beginning of the outbreak is called *reference*


519 *scenario*, described using dark brown bars. Light yellow bars indicate scenarios

520 including vaccination and/or different levels of NPIs. b) Reduction in the cumulative

521 number of symptomatic cases with respect to the *reference scenario*. Orange bars and

522 black values indicate the contribution of NPIs, blue bars and black values indicate the

523 overall contribution of vaccination and NPIs, while the white values indicate net  
524 contribution of vaccination; c)-d) As a-b but for hospitalized cases; e)-f) As a-b but for  
525 cases admitted to ICU; g)-h) As a-b but for deaths. Number denotes median, and error  
526 bars denote quantiles 0.025 and 0.975.



527

528 **Figure 3. Impact of daily vaccine administration capacity on COVID-19 deaths.**


529 a) Cumulative number of COVID-19 deaths (millions) as estimated in the different

530 scenarios under progressively increasing values of the daily vaccination capacity; b)

531 Proportion of deaths averted compared to the *reference scenario*, i.e., *no vaccination*

532 + *no NPIs* with  $R_t=2.5$  at the beginning of the outbreak. Number denotes median, and

533 error bars denote quantiles 0.025 and 0.975.



535 **Figure 4. Best prioritization strategy to achieve the minimal COVID-19 deaths.**

536 Initial cases denote breakthrough COVID-19 cases, which initiates the epidemic. We

537 consider the impact of uncertainty (i.e., “Yes” in the figure, which means 200

538 stochastic model realizations are performed in order to account for the ranges) in

539 contact patterns and relative susceptibility on prioritization, and use their mean values

540 as well (i.e., No). Baseline denotes first prioritizing older adults and individuals with

541 underlying conditions. Number in the box denotes the death toll (median), with t  
542 representing thousand and m representing million. Minimum denotes the lowest  
543 deaths in each scenario on the basis of median value. We compare other strategies to  
544 that with minimum deaths using rank sum test. E.g., in the context of initial  
545 cases=5,000,  $R_t=1.5$  and using mean values of contact patterns and relative  
546 susceptibility, the baseline is the optimal strategy to minimize deaths.

547 **Methods**

548 **SARS-CoV-2 transmission and vaccination models**

549 We developed a model of SARS-CoV-2 transmission and vaccination, based on an  
550 age-structured stochastic susceptible-infectious-removed (SIR) scheme, accounting  
551 for heterogeneous mixing patterns by age as estimated in Shanghai<sup>13</sup>. The Chinese  
552 population was distributed in 18 age groups (17 5-year age groups from 0 to 84 years  
553 and one age group for individuals aged 85 years or older)<sup>57</sup>. Each age group was  
554 further split into two subgroups: individuals with or without underlying conditions,  
555 where the former was considered to be associated with an increased risk of severe  
556 outcome of COVID-19<sup>14</sup>.

557

558 In the main analysis, susceptibility to SARS-CoV-2 infection was assumed to be  
559 heterogeneous across ages. Children under 15 years of age were considered less  
560 susceptible to infection compared to adults aged 15 to 65 years, while the older adults  
561 more susceptible<sup>33,34</sup>. Homogeneous susceptibility across age groups was explored in  
562 sensitivity analysis (*SA19*). Asymptomatic and symptomatic individuals were  
563 assumed to be equally infectious<sup>33,34</sup>, and infectiousness was also assumed to be the  
564 same across age groups<sup>33,34</sup>.

565

566 Vaccine is administered with a two-dose schedule. In the baseline model, we assumed  
567 that: i) vaccination reduces susceptibility to SARS-CoV-2 infection; ii) only  
568 susceptible individuals are eligible for vaccination, i.e., we excluded all individuals



569 that have experienced SARS-CoV-2 infection; iii) duration of vaccine-induced

570 protection lasts longer than the time horizon considered (2 years).

571 The baseline model is schematically represented in Supplementary Fig.1 and it is

572 described by differential systems presented in Supplementary File 1-2.

573

#### 574 **Model initialization**

575 In China, the first pandemic wave of COVID-19 was controlled by intense NPIs <sup>58,59</sup>.

576 Almost the entire population of mainland China is still susceptible to COVID-19 <sup>3</sup>. As

577 such, the model is initialized with a fully susceptible population.

578

579 China has been facing mounting pressure of imported COVID-19 cases. Containment

580 of COVID-19 has been possible only through a combination of measures such as

581 complete- or partial-lockdown, citywide mass-screening using

582 reverse-transcriptase–polymerase-chain-reaction (RT-PCR) testing, tracing of contacts

583 and contacts of contacts of COVID-19 cases, which were promptly applied wherever

584 COVID-19 transmission has popped up in mainland China <sup>60</sup>. Despite all the efforts,

585 containment of COVID-19 appears a whack-a-mole game and sporadic outbreaks

586 inevitably occur. Simulations are thus initialized with 40 cases, roughly corresponding

587 to the number of cases with symptoms onset in Beijing before the detection of a local

588 outbreak in June 11, 2020 <sup>61</sup>.

589

#### 590 **Vaccination scenarios**

591 To explore the impact of vaccination, we ran a set of simulations in which neither  
592 NPIs nor vaccination are implemented as a *reference scenario* (*no vax + no NPIs*, i.e.,  
593 effective reproductive number  $R_t=2.5$  at the beginning of simulations<sup>17,28,58</sup>), and  
594 compared it with a scenario in which vaccination only is implemented (*vax + no*  
595 *NPIs*). Further, we considered different sets of simulations in which NPIs are used to  
596 bring  $R_t$  respectively down to 1.5 (mild NPIs), 1.3 (moderate NPIs), and 1.1 (high  
597 NPIs), with (*vax + mild/moderate/high NPIs*) or without vaccination program (*no vax*  
598 *+ mild/moderate/high NPIs*). In the main analysis vaccination is assumed to begin 15  
599 days after the epidemic start. Alternative scenarios about the seeding of the epidemic  
600 were explored as sensitivity analyses. In particular, we considered the epidemic to  
601 start when 10% (*SA1*), 20% (*SA2*), and 30% (*SA3*) of the Chinese population has  
602 already been vaccinated.

603

604 The model is run considering daily time steps. Gradual delivery of vaccine doses is  
605 implemented by vaccinating a fixed number of individuals each day. Although  
606 manufacturers state that a total of 3.9 billion doses of vaccines could be available by  
607 the end of 2021<sup>22-26</sup>, scale-up and delivery will take months. On the basis of the 2009  
608 H1N1 influenza pandemic vaccination program implemented in mainland China<sup>62</sup>, in  
609 the main analysis we assumed 6 million doses of COVID-19 vaccines could be  
610 administered each day (4 doses per 1,000 individuals) until uptake reaches 70% for all  
611 groups<sup>14</sup>. Different values of the daily vaccine administration capacity, i.e., 1.3  
612 (*SA20*), 10 (*SA21*), 15 (*SA22*), 30 (*SA23*) million dose per day, are explored in

613 separate sensitivity analyses. Sensitivity analyses were also performed on the  
614 vaccination coverage which is assumed either to be homogenous (*SA4* and *SA5*)<sup>14</sup> or  
615 heterogeneous by age (*SA6*, *SA7*, and *SA8*).

616

617 In the main analysis, vaccination is administered to susceptible individuals only. This  
618 represents an ideal scenario where we assume that all infected individuals can be  
619 identified (e.g., either via RT-PCR while infected or via serological assays later one)  
620 and that SARS-CoV-2 infection confers a long-lasting immunity. Since infection  
621 ascertainment could be challenging and pose additional strain to the health system, we  
622 also consider two sensitivity analyses in which only detected symptomatic cases are  
623 excluded from vaccination (*SA14-SA15*).

624

625 In the context of fast RT-PCR–based mass screening if there is an outbreak,  
626 under-ascertainment of symptomatic cases could be only related with the sensitivity  
627 of RT-PCR tests. The sensitivity is quite high (98%) if the interval between symptom  
628 onset and RT-PCR test is within 7 days, and the sensitivity decreases to 68% if the  
629 time interval is 8-14 days<sup>63</sup>. The mean time interval from symptom onset to the date  
630 of collection of the sample for PCR testing was estimated to be 4.7 days in Hunan<sup>33</sup>.  
631 Accordingly, we considered as ascertainment probabilities of symptomatic cases 70%  
632 (*SA14*) and 90% (*SA15*).

633

634 ***Vaccination schedule and efficacy***

635 There are six COVID-19 vaccines developed by China in phase 3 clinical trials,  
636 including five vaccines administered with a two-dose schedule with an interval of 14,  
637 21, or 28 days and one single-dose recombinant adenovirus type-5-vectored vaccine.  
638 For simplicity, in the main analysis, we modeled the administration of an inactivated  
639 vaccine developed by the Beijing Institute of Biological Products,<sup>64</sup> which entail a  
640 two-dose schedule across all age groups with an interval of 21 days. In separate  
641 sensitivity analyses, we explored an interval of 14 days and 28 days (*SA16-SA17*).  
642  
643 China approved its first local COVID-19 vaccine (developed by Sinopharm) for  
644 general public use on December 31, 2020, with an estimated vaccine efficacy (VE) of  
645 79.3%.<sup>21</sup> In the main analysis, we used a VE of 80% against infection in individuals  
646 aged 20-59 years. In the developed model, vaccination confers a partial protection, i.e.,  
647 vaccinated individuals are 80% less likely to develop infection upon an infectious  
648 contact. Sensitivity analyses using a VE of 60% (*SA9*) and 90% (*SA10*) were  
649 separately performed. The alternative values of VE were selected on the basis of  
650 published upper efficacy of vaccines of 94-95% and in such a way to cover a  
651 plausible efficacy range of forthcoming vaccines<sup>65-67</sup>.  
652  
653 Phase 2 clinical trials demonstrated that vaccine immunogenicity was lower among  
654 older individuals than in younger adults<sup>64</sup>. And for other inactivated vaccines like  
655 influenza vaccine, a lower VE is observed in children compared to young adults<sup>68</sup>.  
656 Accordingly, we assumed an age-dependent VE. In particular, given a baseline

657 efficacy VE among individuals aged 20-59 years (80% in the main analysis), we  
658 assumed a 50% lower VE in individuals <20 and  $\geq 60$  years of age (namely 40%). A  
659 scenario without age-specific variations in VE was explored as sensitivity analysis  
660 (*SA24*).

661

662 Individuals vaccinated with the first dose could still develop infections without any  
663 immune protection, while the second dose vaccination could produce the expected  
664 vaccine efficacy after an average of 14 days. In the main analysis we assume both  
665 natural infection-induced and vaccine-induced immunity to SARS-CoV-2 infection  
666 does not wane within the considered time horizon (2 years). In additional sensitivity  
667 analyses, we considered an average duration of vaccine-induced protection of 6  
668 months (*SA12*) and 1 year (*SA25*). We also consider a sensitivity analysis assuming  
669 that vaccination is effective in preventing symptomatic illness, but not infection  
670 (*SA11*), and another one assuming an all-or-nothing vaccine, i.e., the vaccine confers  
671 full protection to VE percent of vaccinated individuals (*SA18*).

672

### 673 ***Priority order of vaccination***

674 The doses available to be distributed daily (6 million in the main analysis) are  
675 assigned by considering the following order of priority<sup>14</sup>. In the main analysis,  
676 healthcare workers are considered as the top priority (Tier 1 of the vaccination  
677 strategy); law enforcement and security workers, personnel in nursing home and  
678 social welfare institutes, community workers, workers in energy, food and

679 transportation sectors are included in Tier 2; adults  $\geq 60$  years of age with underlying  
680 conditions, and adults  $\geq 80$  years of age without underlying conditions, who are at the  
681 highest risk of severe/fatal COVID-19, are considered in Tier 3; individuals aged  $< 60$   
682 years with pre-existing medical conditions and pregnant women are included in Tier 4;  
683 individuals aged 20-59 years without underlying conditions are included in Tier 5;  
684 school-age children and younger children aged  $\leq 5$  years without underlying  
685 conditions are recommended for vaccination in Tier 6 (Supplementary File 4).

686

687 Different priority orders are explored as sensitivity analyses. Healthcare workers and  
688 the other essential workers listed above are fixed in Tier 1 and Tier 2 of vaccination,  
689 while the remaining population is vaccinated as described in Supplementary Table 2  
690 by considering different orders of prioritization only based on age and disregarding  
691 the presence of underlying conditions (*SA26*: first prioritization to old adults; *SA27*:  
692 first prioritization to working-age groups; *SA28*: first prioritization to school-age  
693 groups). We explore the impact of 5,000 initial cases on the prioritization strategy  
694 (*SA29*). To understand the impact in terms of number of infections by age, we  
695 compare the prioritization strategy when we account for the uncertainty in the contact  
696 matrix and in the susceptibility to infection by age, or not (in this context, median  
697 values of contact numbers and relative susceptibility are used).

698

### 699 **COVID-19 burden model**

700 The main output of above transmission model is the age-specific number of new

701 infections per day in the subpopulation with or without underlying conditions. On top  
702 of that, we developed a model of COVID-19 disease burden to estimate the number of  
703 symptomatic cases, hospitalization, ICU admissions, and deaths in different scenarios  
704 in the presence/absence of vaccination.

705

706 We computed the age-specific number of symptomatic infections in individuals with  
707 and without underlying conditions on a daily-basis, by applying an age-specific  
708 probability of respiratory symptoms, which is 18.1%, 22.4%, 30.5%, 35.5%, and 64.6%  
709 separately for 0-19, 20-39, 40-59, 60-79, and 80+ years of age, as estimated from  
710 contact tracing data in Lombardy<sup>20</sup>. We assume that individuals with and without  
711 underlying conditions have the same age-specific probability of developing  
712 symptoms.

713

714 The daily age-specific number of hospital admissions in the two subpopulations was  
715 computed by applying the age-specific proportion of laboratory-confirmed  
716 symptomatic cases requiring hospitalizations (Supplementary File 5), delayed by an  
717 average time of 3.8 days between symptom onset and hospitalization<sup>17</sup>.

718 The daily age-specific number of patients admitted to ICU in the two subpopulations  
719 was computed by applying to hospitalized cases an age-specific probability of being  
720 admitted to ICU<sup>19</sup>, and distinguishing patients requiring intensive care in survivors  
721 and non-survivors. Survivors are admitted to ICU after an average time of 7 days  
722 from hospitalization. Non-survivors are admitted to ICU after an average time of 8

723 days after hospitalization <sup>16</sup>.

724

725 The daily age-specific number of deaths in the two subpopulations was computed by  
726 applying the age-specific fatality ratio among symptomatic cases (Supplementary File  
727 5), delayed by an average time of 13.9 days between symptom onset and death <sup>18</sup>.

728

### 729 **Data analysis**

730 For each scenario, 200 stochastic model realizations were performed. The outcome of  
731 these simulations determined the distributions of the number of symptomatic  
732 infections, hospitalizations, ICU admissions, and deaths. 95% confidence intervals  
733 were defined as quantiles 0.025 and 0.975 of the estimated distributions. We used a  
734 Bayesian approach to estimate  $R_t$  from the time series of symptomatic cases by date  
735 of symptom onset and the distribution of the serial interval <sup>17</sup>. The methods were  
736 described in Supplementary File 6 in details.

737

738 **Ethics approval** All these data were in the public domain. Ethical review for the  
739 re-use of these secondary data is not required.

740

### 741 **Reporting summary**

742 Further information on research design is available in the Nature Research Reporting  
743 Summary linked to this paper.

744



745 **Data and code availability**

746 Should the manuscript be accepted, all data and codes will be provided on *GitHub*.

747 **References**

- 748 1. Johns Hopkins University Coronavirus Research Center. New cases of COVID-19 in  
749 world. <https://coronavirus.jhu.edu/data/new-cases> (2021).
- 750 2. Zhao, J. et al. Disease Burden Attributable to the First Wave of COVID-19 in China  
751 and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies.  
752 *Value Health* **24**, 615-624 (2021).
- 753 3. Chen, X. et al. Serological evidence of human infection with SARS-CoV-2: a  
754 systematic review and meta-analysis. *Lancet Glob Health* **9**, e598-e609 (2021).
- 755 4. Our World in Data. Coronavirus (COVID-19) Vaccinations.  
756 <https://ourworldindata.org/covid-vaccinations> (2021).
- 757 5. Wang, W. et al. Global, regional, and national estimates of target population sizes for  
758 covid-19 vaccination: descriptive study. *BMJ* **371**, m4704 (2020).
- 759 6. Press Conference of the Joint Prevention and Control Mechanism of the State  
760 Council. Introduction to the promotion of COVID-19 vaccination (Up to May 7).  
761 [http://www.gov.cn/xinwen/2021-05/08/content\\_5605360.htm](http://www.gov.cn/xinwen/2021-05/08/content_5605360.htm) (2021).
- 762 7. National Health Commission of the People's Republic of China. Outbreak report.  
763 [http://www.nhc.gov.cn/xcs/yqtb/list\\_gzbd.shtml](http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml) (2021).
- 764 8. Anderson, R.M. & May, R.M. Vaccination and herd immunity to infectious diseases.  
765 *Nature* **318**, 323-329 (1985).
- 766 9. Agur, Z., Cojocaru, L., Mazor, G., Anderson, R.M. & Danon, Y.L. Pulse mass measles  
767 vaccination across age cohorts. *Proc Natl Acad Sci U S A* **90**, 11698-11702 (1993).
- 768 10. Chao, D.L., Halloran, M.E. & Longini, I.M., Jr. Vaccination strategies for epidemic

- 769 cholera in Haiti with implications for the developing world. *Proc Natl Acad Sci U S A*  
770 **108**, 7081-7085 (2011).
- 771 11. Ferguson, N.M., Donnelly, C.A. & Anderson, R.M. The foot-and-mouth epidemic in  
772 Great Britain: pattern of spread and impact of interventions. *Science* **292**, 1155-1160  
773 (2001).
- 774 12. Wu, J.T., Peak, C.M., Leung, G.M. & Lipsitch, M. Fractional dosing of yellow fever  
775 vaccine to extend supply: a modelling study. *Lancet* **388**, 2904-2911 (2016).
- 776 13. Zhang, J. et al. Patterns of human social contact and contact with animals in  
777 Shanghai, China. *Sci Rep* **9**, 15141 (2019).
- 778 14. Yang, J. et al. Who should be prioritized for COVID-19 vaccination in China? A  
779 descriptive study. *BMC Med* **19**, 45 (2021).
- 780 15. Yang, J. et al. Disease burden and clinical severity of the first pandemic wave of  
781 COVID-19 in Wuhan, China. *Nat Commun* **11**, 5411 (2020).
- 782 16. Xie, J. et al. Clinical characteristics and outcomes of critically ill patients with novel  
783 coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study.  
784 *Intensive Care Med* **46**, 1863–1872 (2020).
- 785 17. Zhang, J. et al. Evolving epidemiology and transmission dynamics of coronavirus  
786 disease 2019 outside Hubei province, China: a descriptive and modelling study.  
787 *Lancet Infect Dis* **20**, 793-802 (2020).
- 788 18. Deng, X. et al. Case fatality risk of the first pandemic wave of novel coronavirus  
789 disease 2019 (COVID-19) in China. *Clin Infect Dis*, ciaa578 (2020).
- 790 19. Guan, W. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl*

- 791 *J Med* **382**, 1708-1720 (2020).
- 792 20. Poletti, P. et al. Association of Age With Likelihood of Developing Symptoms and  
793 Critical Disease Among Close Contacts Exposed to Patients With Confirmed  
794 SARS-CoV-2 Infection in Italy. *JAMA Netw Open* **4**, e211085 (2021).
- 795 21. Sinopharm. Sinopharm COVID-19 vaccine licensed in China.  
796 <http://www.sinopharm.com/s/1223-3763-38840.html> (2021).
- 797 22. CNWest. Curret development and production capacity of domestic COVID-19 vaccine.  
798 <http://news.cnwest.com/szyw/a/2020/12/04/19343015.html> (2021).
- 799 23. Huanqiu Net. Chairman of Cansino Bio: After the increase in production capacity, the  
800 company's COVID-19 vaccine will be released in large quantities.  
801 <https://baijiahao.baidu.com/s?id=1692936657439211781&wfr=spider&for=pc> (2021).
- 802 24. Sinopharm. The first batch of BBIBP-CorV(Sinopharm) has shipped.  
803 <http://www.sinopharm.com/s/1223-3769-39020.html> (2021).
- 804 25. Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will  
805 reach 2 billion doses by June.  
806 <https://cn.reuters.com/article/sinovac-biotech-covid-vaccine-0303-idCNKCS2AV0DL>  
807 (2021).
- 808 26. Sinopharm. Chinese and foreign media enter the 1 billion-level COVID-19 vaccine  
809 production base. <http://www.sinopharm.com/s/1223-4126-39018.html> (2021).
- 810 27. Wu, J.T., Leung, K. & Leung, G.M. Nowcasting and forecasting the potential domestic  
811 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a  
812 modelling study. *Lancet* **395**, 689-697 (2020).

- 813 28. Li, Q. et al. Early Transmission Dynamics in Wuhan, China, of Novel  
814 Coronavirus-Infected Pneumonia. *N Engl J Med* **382**, 1199-1207 (2020).
- 815 29. Abbott, S., Hellewell, J., Munday, J., group, C.n.w. & Funk, S. The transmissibility of  
816 novel Coronavirus in the early stages of the 2019-20 outbreak in Wuhan: Exploring  
817 initial point-source exposure sizes and durations using scenario analysis. *Wellcome*  
818 *Open Res* **5**, 17 (2020).
- 819 30. Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel  
820 coronavirus (COVID-19) outbreak. *Science* **368**, 395-400 (2020).
- 821 31. Natsuko, I. et al. Report 3: Transmissibility of 2019-nCoV. Imperial College London.  
822 <https://doi.org/10.25561/77148> (2020)
- 823 32. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus  
824 Disease 2019 (COVID-19).  
825 <https://www.who.int/publications/item/report-of-the-who-china-joint-mission-on-coron>  
826 [avirus-disease-2019-\(covid-19\)](https://www.who.int/publications/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)) (2021).
- 827 33. Hu, S. et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2  
828 transmission under intensive contact tracing in Hunan, China. *Nature*  
829 *Communications* **12**, 1533 (2021).
- 830 34. Sun, K. et al. Transmission heterogeneities, kinetics, and controllability of  
831 SARS-CoV-2. *Science*, eabe2424.
- 832 35. Li, L. et al. Influenza-associated excess respiratory mortality in China, 2010-15: a  
833 population-based study. *The Lancet. Public health* **4**, e473-e481 (2019).
- 834 36. Wang, J. et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic

- 835 in China. *Vaccines* **8**, 482 (2020).
- 836 37. Wang, J. et al. The Changing Acceptance of COVID-19 Vaccination in Different  
837 Epidemic Phases in China: A Longitudinal Study. *Vaccines (Basel)* **9**(2021).
- 838 38. Shao, G., Ding, W., Yu, Y., Ma, H. & Zhijie, A. Willingness of parents to vaccinate  
839 family members with coronavirus disease 2019, influenza, and pneumococcal  
840 vaccines, Anyang city, May to June 2020. *Chinese Journal of Vaccines and*  
841 *Immunization* (2020).
- 842 39. SINOVAC. Supply Vaccines to Eliminate Human Diseases.  
843 [http://www.sinovac.com.cn/?optionid=468&auto\\_id=1877](http://www.sinovac.com.cn/?optionid=468&auto_id=1877) (2021).
- 844 40. CanSinoBIO. The application for conditional marketing of CansinoBio Coronavirus  
845 Vaccine ConvideciaTM was accepted by the National Medical Products  
846 Administration. <http://www.cansinotech.com.cn/html/1///179/180/806.html> (2021).
- 847 41. Beijing Institute of Biological Products Co., LTD. Products Instruction.  
848 <https://www.bjbpi.com/?p=75> (2021).
- 849 42. Palacios, R. et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in  
850 Healthcare Professionals in Brazil: The PROFISCOV Study. Preprint at *SSRN*  
851 [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3822780](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780) (2021).
- 852 43. Wuhan Institute of Biological Products Co., LTD. The interim analysis data of the  
853 COVID-19 inactivated vaccine phase III clinical trial of Sinopharm Wuhan Institute of  
854 Biological Products released. <http://www.wibp.com.cn/Chs/Detail.aspx?id=14669>  
855 (2021).
- 856 44. Centers for Disease Control and Prevention. About Variants of the Virus that Causes

- 857 COVID-19. <https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html>  
858 (2021).
- 859 45. Davies, N.G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage  
860 B.1.1.7 in England. *Science*, eabg3055 (2021).
- 861 46. Stefanelli, P. et al. Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1. Preprint at  
862 *medRxiv* <https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1> (2021).
- 863 47. Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of  
864 concern 202012/1: matched cohort study. *BMJ* **372**, n579 (2021).
- 865 48. Davies, N.G. et al. Increased mortality in community-tested cases of SARS-CoV-2  
866 lineage B.1.1.7. *Nature* (2021).
- 867 49. Meehan, M.T. et al. Age-targeted dose allocation can halve COVID-19 vaccine  
868 requirements. Preprint at *medRxiv*  
869 <https://www.medrxiv.org/content/10.1101/2020.10.08.20208108v2> (2020).
- 870 50. Zhang, J. et al. The impact of relaxing interventions on human contact patterns and  
871 SARS-CoV-2 transmission in China. *Science Advances* **7**, eabe2584 (2020).
- 872 51. Bubar, K.M. et al. Model-informed COVID-19 vaccine prioritization strategies by age  
873 and serostatus. *Science* **371**, 916-921 (2021).
- 874 52. Giordano, G. et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the  
875 requirement for non-pharmaceutical interventions in Italy. *Nat Med* (2021).
- 876 53. Li, Y. et al. The temporal association of introducing and lifting non-pharmaceutical  
877 interventions with the time-varying reproduction number (R) of SARS-CoV-2: a  
878 modelling study across 131 countries. *Lancet Infect. Dis.* **21**, 193-202 (2021).

- 879 54. Wibmer, C.K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African  
880 COVID-19 donor plasma. Preprint at *bioRxiv*  
881 <http://biorxiv.org/content/early/2021/01/19/2021.01.18.427166.abstract> (2021).
- 882 55. Han, S. et al. Dynamic optimization of COVID-19 vaccine prioritization in the context of  
883 limited supply. Preprint at *Nature Portfolio*  
884 <https://www.researchsquare.com/article/rs-257573/v1> (2021).
- 885 56. Liu, Q.H. et al. Measurability of the epidemic reproduction number in data-driven  
886 contact networks. *Proc Natl Acad Sci U S A* **115**, 12680-12685 (2018).
- 887 57. Population Division, Department of Economic and Social Affairs, United Nations.  
888 World Population Prospects 2019. <https://population.un.org/wpp/> (2019).
- 889 58. Pan, A. et al. Association of Public Health Interventions With the Epidemiology of the  
890 COVID-19 Outbreak in Wuhan, China. *JAMA* **323**, 1915-1923 (2020).
- 891 59. Li, Z. et al. Active case finding with case management: the key to tackling the  
892 COVID-19 pandemic. *Lancet* **396**, 63-70 (2020).
- 893 60. Xing, Y., Wong, G.W.K., Ni, W., Hu, X. & Xing, Q. Rapid Response to an Outbreak in  
894 Qingdao, China. *N Engl J Med* **383**, e129 (2020).
- 895 61. Xinhua net. The COVID-19 outbreak in Beijing.  
896 [http://www.xinhuanet.com/politics/2020-06/19/c\\_1126135352.htm](http://www.xinhuanet.com/politics/2020-06/19/c_1126135352.htm) (2020).
- 897 62. The Central People's Government of the People's Republic of China. Report of H1N1  
898 pandemic influenza vaccination from Ministry of Health. <http://www.gov.cn/gzdt>  
899 (2020).
- 900 63. Xiao, A. et al. Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in



- 901            Wuhan, China: A Descriptive Study. *Journal of Clinical Virology* **127**, 104346 (2020).
- 902    64.    Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,  
903            BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet*  
904            *Infect Dis* **21**, 39-51 (2021).
- 905    65.    Callaway, E. COVID vaccine excitement builds as Moderna reports third positive  
906            result. *Nature* **587**, 337-338 (2020).
- 907    66.    Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)  
908            against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,  
909            South Africa, and the UK. *Lancet* **397**, 99-111 (2021).
- 910    67.    Polack, F.P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*  
911            *Engl J Med* **383**, 2603-2615 (2020).
- 912    68.    Yang, P. et al. Influenza vaccine effectiveness against medically-attended influenza  
913            illness during the 2012-2013 season in Beijing, China. *Vaccine* **32**, 5285-5289 (2014).
- 914

915 **End notes**

916 **Acknowledgments**

917 The study was supported by grants from the National Science Fund for Distinguished  
918 Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and  
919 Technology Committee (No 20411950100), European Union Grant 874850 MOOD  
920 (MOOD 000).

921

922 **Author Contributions**

923 H.Y. conceived the study. H.Y., S.M., and M.A. designed and supervised the study.  
924 J.Y., J. Z., J.C., W.W., Q.W., W.Z., Z.Z, K.D., and G.Z. participated in data collection.  
925 V.M., G.G., P.P., and F.T. developed the model. V.M., J.Y., and X.D. analyzed the  
926 model outputs and prepared the tables and figures. J.Y. prepared the first draft of the  
927 manuscript. H.Y., V.M., and M.A. commented on the data and its interpretation,  
928 revised the content critically. All authors contributed to review and revision and  
929 approved the final manuscript as submitted and agree to be accountable for all aspects  
930 of the work.

931

932 **Declaration of interests**

933 H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang  
934 HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical  
935 Company. M.A. has received research funding from Seqirus. None of those research  
936 funding is related to COVID-19. All other authors report no competing interests.

937

938 **Disclaimer**

939 This article does not necessarily represent the views of the NIH or the US

940 government.

941

942 **Additional information**

943 **Supplementary Information** is available for this paper.

944 **Correspondence and requests for materials** should be addressed to M.A., and H.Y.

945 **Peer review information.**

946 **Reprints and permissions information** is available at

947 <http://www.nature.com/reprints>.